stand welcome third quarter earn conference call operator instruction would like introduce vice president investor relation proceed vice president investor relation good morning thank join also call today chairman board chief executive officer vice chairman president executive vice president chief financial officer executive vice president commercial operation start statement make today consider forward look statement purpose private security litigation reform caution forward look statement subject risk uncertainty cause actual result differ materially indicate forward look statement additional information risk uncertainty include file undertake obligation update forward look statement except require today conference call financial measure help investor understand business performance financial measure reconcile comparable financial measure earn release regulatory file today find website unless otherwise note commentary sale growth comparable basis include full current year historical result comparison underlie performance historically report revenue recast conform revenue recognition account policy exclude divestiture reference operational growth exclude impact exchange follow prepare remark take question turn call chairman board chief executive officer thank good morning everyone thank join today third quarter performance outlook review business highlight pipeline progress financial result detail continue perform deliver outstanding quarter adjust earn share exceed midpoint guidance total adjust revenue billion operational basis balance growth across major growth platform continue double digit revenue growth immunology skyrizi rinvoq establish strong launch trajectory asset either approve regulatory review late stage development across major indication remain confident significant contributor long term growth aesthetic also demonstrate impressive double digit operational sale growth dedicate global aesthetic structure increase investment drive accelerate category growth across toxin pillar substantial room additional market penetration strategic investment target field force expansion improve overall customer retention rate significantly increase number first time patient lead brand raise full year guidance aesthetic quarter view portfolio extremely attractive growth opportunity long term high single digit compound annual growth rate expect decade neuroscience business drive robust double digit revenue performance quarter product migraine portfolio approval daily oral medication preventative treatment episodic migraine hematological oncology portfolio deliver operational sale growth approximately quarter despite market recovery remain level beyond significant contribution imbruvica venclexta excite oncology pipeline several promise program development blood cancer solid tumor support sustainable long term growth include navitoclax myelofibrosis eculizumab cell malignancy multiple myeloma lemzoparlimab ubrelvy squamous small cell lung cancer lastly continue make excellent progress integration financial result show create stronger much diverse company numerous product across newly combine portfolio deliver robust growth overall extremely please momentum raise full year guidance expect adjust earn share reflect growth nearly midpoint additionally note news release today announce increase quarterly cash dividend share share begin dividend payable since inception grow quarterly dividend summary demonstrate strong execution across portfolio assemble impressive diversify asset significant growth potential give high degree confidence long term outlook business turn call executive vice president commercial operation thank continue demonstrate strong balance growth across therapeutic portfolio start immunology remain position sustain leadership portfolio best class medicine total immunology revenue approximately billion operational basis global sale billion operational basis revenue growth offset biosimilar competition across international market revenue operational basis skyrizi perform extremely global sale nearly million sequential basis reflect continue market share gain skyrizi lead play psoriasis patient share include switch patient roughly double share capture next nearest biologic competitor skyrizi total prescription share psoriasis biologic market nearly second internationally skyrizi continue ramp nicely also achieve play patient share leadership dozen market share performance support important near term enhancement availability simple delivery form skyrizi potential indication expansion psoriatic arthritis first recently launch convenient skyrizi single dose milligram self injectable syringe major territory around world market response favorable approval make skyrizi quarterly dose brand available single self injectable patient second prepare global launch skyrizi psoriatic arthritis near approval decision receive positive opinion earlier month anticipate approval year continue expect approval early next year addition indication approve round skyrizi dermatology label give patient access therapeutic option also make excellent progress skyrizi development disease recently submit regulatory review commercialization expect next year rinvoq also continue demonstrate robust growth global sale million nearly sequential basis total play share remain strong reflect approximately patient share leadership half dozen country around world internationally rinvoq share continue ramp make excellent progress recent commercial launch atopic dermatitis secure strong label indication many aware issue safety communication regard update inhibitor include rinvoq early update label closely monitor prescription trend feedback field observe significant impact rinvoq utilization time update label restrict inadequate responder would certainly expect near term impact patient start base robust data generate across development program multiple biologics later line therapy expect rinvoq ultimately obtain higher share growth second line plus patient ultimately fail therapy time overall continue feel good performance profile rinvoq remain confident asset major contributor long term growth hematologic oncology global revenue nearly billion operational basis imbruvica venclexta strong position across multiple heme indication include combine portfolio remain clear market share leader across line therapy global imbruvica revenue approximately billion performance continue primarily impact slower expect market recovery modest share erosion newer therapy include venclexta inhibitor patient start remain level difficult predict dynamic fully recover venclexta sale operational basis increase momentum across indication include strong launch trajectory international market neuroscience revenue nearly billion operational basis particularly please result outlook emerge migraine portfolio company portfolio distinctive therapy address spectrum common complex disease include therapeutic unique foundational treatment prevention chronic migraine perform total sale million therapeutic operational basis ubrelvy lead oral treatment acute migraine also demonstrate rapid growth total sale million nearly sequential basis base ubrelvy competitive profile continue strong patient start rapidly expand market remain confident ubrelvy represent billion plus sale opportunity launch oral specifically develop preventative treatment migraine already excellent start early feedback physician positive give strong efficacy safety convenient dose profile relative current standard care launch support exist migraine sale force commercial access expect ramp strongly first half also represent billion plus sale opportunity believe three distinct competitively position therapy across spectrum migraine condition therapeutic ubrelvy optimize specific migraine indication enable physician tailor treatment broadest range patient portfolio migraine therapy strong position capture growth dynamic market turn psychiatry also robust performance vraylar remain fastest grow atypical antipsychotic total revenue million operational basis continue strong demand across schizophrenia bipolar disorder bipolar depression lastly therapeutic area significant contribution care revenue million operational basis sale million operational basis treat patient volume still remain suppress compare level double digit growth operationally overall please continue execution across therapeutic portfolio demonstrate strong revenue growth turn call additional comment program vice chairman president thank start immunology several regulatory update data readout rinvoq skyrizi across therapeutic area follow successful completion registrational program rinvoq ulcerative colitis skyrizi disease submit regulatory application asset respective indication strong data rinvoq skyrizi induction maintenance treatment respectively base result believe drug potential become highly effective differentiate therapy indication anticipate approval decision earlier month announce positive line result phase select axis program rinvoq axial include data stand alone study spondylitis patient inadequate response biologics another patient radiographic axial spondylitis study rinvoq perform demonstrate significantly greater improvement sign symptom physical function image endpoint compare placebo level efficacy difficult treat refractory population similar typically observe naive patient result submission package rinvoq currently review radiographic axial study rinvoq also perform meet primary secondary endpoint plan submit regulatory application indication later quarter rinvoq safety profile axial trial consistent previous study evidence increase risk event malignancy either study base data generate select access program believe rinvoq potential improve care patient suffer axial provide sustain disease control rapid durable pain reduction improve function likely aware communicate require inhibitor include rinvoq limit certain patient respond tolerate anti continue work regard update label language indication simultaneously engage agency file atopic dermatitis psoriatic arthritis spondylitis remain confident submission package three indication continue expect approval follow completion label update area oncology continue make good progress advance stage pipeline near completion several indication expansion program venclexta study previously untreated higher risk patient recently receive breakthrough therapy designation expect make data early next year include month follow data duration response base data plan submit regulatory application first half accelerate approval continue make good progress venclexta trial evaluate venclexta relapse refractory multiple myeloma patient mutation venclexta show strong anti myeloma activity biomarker define population successful opportunity play important role treatment paradigm multiple myeloma expect data readout event drive trial next year early stage pipeline continue expand cohort epcoritamab phase study diffuse large cell lymphoma follicular lymphoma evaluate epcoritamab monotherapy combination expect data monotherapy combo study next year monotherapy data regulator regard file accelerate approval also recently begin dose escalation stage phase study lemzoparlimab multiple myeloma bispecific antibody currently expansion stage phase study multiple myeloma patient expect begin registrational phase three study next year move neuroscience several notable pipeline event since last earn call receive approval oral specifically design preventative treatment migraine please label reflect strong benefit risk profile support robust clinical development program registrational program evaluate nearly patient suffer episodic migraine treatment result significant reduction mean monthly migraine compare placebo approximately patient achieve least reduction migraine think data compare favorably preventative migraine treatment market believe oral treatment option competitively position prevention market migraine portfolio include ubrelvy acute treatment migraine preventative treatment episodic migraine preventative treatment chronic migraine distinct portfolio uniquely position address full spectrum complex disease morning announce line result phase three study evaluate vraylar adjunctive treatment major depressive disorder study milligram vraylar dose meet primary endpoint demonstrate clinically meaningful improvement total score compare placebo week highly statistically significant value study three milligram vraylar dose reach statistical significance show clear trend toward improvement nominal value approximately week second phase three trial study neither vraylar dose meet primary endpoint change total moderate score week three milligram demonstrate clear trend toward clinically meaningful benefit week four nominal value number comparison additionally reminder prior positive registrational phase study vraylar demonstrate efficacy ongoing antidepressant treat base precedent field totality data believe viable regulatory pathway vraylar adjunctive treatment major depressive disorder plan engage regulatory agency result expect submit regulatory application first half next year also recently announce positive line result phase three study compare novel subcutaneous levodopa carbidopa delivery system oral levodopa carbidopa patient advance disease pivotal study treatment result clinically meaningful improvement time without troublesome dyskinesia similar improvement normalize time compare oral levodopa carbidopa please result believe support view potential become transformative improvement current treatment option patient advance disease plan submit regulatory application next year approval decision anticipate early care announce partnership develop commercialize potential gene therapy treatment diabetic retinopathy chronic retinal disease attractive addition pipeline complement care portfolio potential flagship product retinal disease recently present initial data phase study evaluate diabetic retinopathy office delivery early result encourage demonstrate efficacy lowest dose study show drug delivery method appear tolerate also care continue expect approval beauty shortly formerly know treatment symptom associate presbyopia daily drop develop help address presbyopia often correct read glass approve would convenient demand solution patient mild moderate presbyopia want wear read glass productive year thus organization anticipate several additional milestone come month expect momentum continue next year look milestone fill year turn call additional comment third quarter performance financial outlook executive vice president chief financial officer thank hear deliver outstanding performance quarter also advance strategic priority result demonstrate strong momentum business support long term financial outlook turn third quarter result report adjust earn share compare prior year guidance midpoint include accelerate synergy mark market equity gain total adjust revenue billion operational basis exclude favorable impact foreign exchange adjust operate margin ratio sale improvement basis point versus prior year include adjust gross margin sale adjust investment sale adjust expense sale interest expense million adjust rate previously mention raise full year adjust earn share guidance reflect growth midpoint exclude guidance know intangible amortization specify item guidance continue contemplate full year revenue growth comparable operational basis current rate expect foreign exchange favorable impact full year comparable sale growth imply full year revenue forecast approximately billion include guidance follow update full year assumption expect aesthetic global revenue approximately billion expect international sale approximately billion imbruvica expect global revenue approximately billion reflect slower recovery market expect global sale approximately billion expect organic expense synergy approximately billion look ahead fourth quarter anticipate revenue approach billion current rate expect foreign exchange modest unfavorable impact sale growth expect adjust earn share exclude approximately know intangible amortization specify item finally strong business performance continue support capital allocation priority generate billion free cash flow first nine month year cash balance billion underscore confidence long term outlook today announce increase quarterly cash dividend begin dividend payable remain track achieve billion cumulative debt paydown year deleveraging bring leverage ratio time approximately time close deliver outstanding result financial outlook remain strong turn call back vice president investor relation thank open call question operator instruction operator take first question